Fast Market Research recommends "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" from GBI Research, now available

Boston, MA -- (SBWire) -- 06/28/2013 --Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

Summary

GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barre Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.

View Full Report Details and Table of Contents

The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012-2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications.

Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth.

Scope

- Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019
- Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP
- Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan
- Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology

Companies Mentioned in this Report: Baxter International Inc., Biotest Pharmaceuticals, Bio Products Laboratory Ltd., CSL Behring Limited, Grifols S.A., Octapharma AG

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- End-stage Renal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Elan Corporation, plc (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2012
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2012
- Amgen Inc. (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2012
- Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012
- Pompe Disease (GAA Deficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019